What is Immunome's operating cash flow?

Immunome (IMNM) reported operating cash flow of -$58.64M in Q1 2026.

How has Immunome's operating cash flow changed year-over-year?

Immunome's operating cash flow decreased by 10.5% year-over-year, from -$53.06M to -$58.64M.

What is the long-term trend for Immunome's operating cash flow?

Over 3 years (2021 to 2025), Immunome's operating cash flow has grown at a 118.8% compound annual growth rate (CAGR), from -$18.23M to -$190.92M.

What does operating cash flow mean?

Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Immunome IMNM Operating Cash Flow

Operating Cash Flow at other companies

PfizerPFE

$2.62B+12.0%

Arcus BiosciencesRCUS

-$138M-4.5%

Nuvation BioNUVB

$5.07M+112%

SELLAS Life Sciences Group, Inc.SLS

-$8.85M+2.5%

IDEAYA Biosciences, Inc.IDYA

-$75.17M-24.6%

ImmunityBio, Inc.IBRX

-$75.36M+12.3%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's operating cash flow?: Immunome (IMNM) reported operating cash flow of -$58.64M in Q1 2026.
How has Immunome's operating cash flow changed year-over-year?: Immunome's operating cash flow decreased by 10.5% year-over-year, from -$53.06M to -$58.64M.
What is the long-term trend for Immunome's operating cash flow?: Over 3 years (2021 to 2025), Immunome's operating cash flow has grown at a 118.8% compound annual growth rate (CAGR), from -$18.23M to -$190.92M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.